Table 2.
Common toxic effects: serious adverse events
| Grade | Category | Toxicity | Total no. of patients (N = 25) |
| Grade 1 | Allergy/immunology | Allergy/immunology—other | 1 |
| Dermatology/skin | Dermatology/skin—other | 1 | |
| Metabolic/laboratory | Sodium, serum—low (hyponatremia) | 1 | |
| Grade 2 | Neurology | Mental status | 1 |
| Cardiac general | Hypotension | 1 | |
| Dermatology/skin | Flushing | 1 | |
| Gastrointestinal | Dehydration | 1 | |
| Nausea | 1 | ||
| Musculoskeletal/soft tissue | Fracture | 1 | |
| Pain | Pain—other | 1 | |
| Pulmonary/upper respiratory | Dyspnea | 1 | |
| Pulmonary/upper respiratory—other | 1 | ||
| Grade 3 | Gastrointestinal | Nausea | 1 |
| Vomiting | 3 | ||
| Diarrhea | 3 | ||
| Mucositis/stomatitis—oral cavity | 1 | ||
| Neurology | Seizure | 1 | |
| Grade 4 | Metabolic/laboratory | Calcium, serum high (hypercalcemia) | 1 |
| Hemorrhage/bleeding | Hemorrhage, gastrointestinal—oral cavity | 1 | |
| Grade 5 | Death | Death not associated with CTCAE term—disease progression NOS | 1 |
| Death not associated with CTCAE term—sudden death | 1 |
CTCAE, Common Toxicity Criteria Adverse Event; NOS, not otherwise specified.